Medications for myelofibrosis are used to treat this bone marrow condition, which can happen as a complication of polycythemia vera and essential thrombocythemia. They work by targeting specific pathways in the body to reduce symptoms and slow progression of the blood condition. Common classes include Janus kinase (JAK) inhibitors and other kinase inhibitors. JAK inhibitors like Jakafi (ruxolitinib) are usually taken as oral pills. Other options, such as Inrebic (fedratinib) and Ojjaara (momelotinib), are also available in oral form. These treatments offer different ways to help manage your condition effectively.
